NCT03235765

Cancer Panel From Blood of Lung Cancer Patients

Clinical Validity of Oncogenic Driver Genes Detected From Circulating Tumor DNA in Blood of Lung Cancer Patients

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 200 (estimated)
• Sponsor: Seoul National University Hospital · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

Molecular profiling of lung cancers using circulating tumor DNA (ctDNA) in the blood of patients is rapidly becoming established as a useful source of information to aid clinical decision-making. This study is aimed to to compare concordance rate between tissue based cancer panel analysis and blood based cancer panel analysis in lung cancer patients (both by NGS technique).

Detailed description

This study is comprised of two cohorts as below: Cohort A: inoperable, untreated, non-small cell lung cancer patients Cohort B: non-small cell lung cancer patients who are in the treatment with targeted agents including immune checkpoint inhibitors

Conditions

• Non Small Cell Lung Cancer Metastatic
• Non Small Cell Lung Cancer Recurrent

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	MACROGEN Pan Cancer Panel (Tier 2)	This study will utilize a MACROGEN Pan Cancer Panel (Tier 2), which is a hybrid capture-based NGS assay interrogating the coding regions of 170 cancer-related genes.

Timeline

• Start date: 2017-03-10
• Primary completion: 2019-03-10
• Completion: 2020-03-10
• First posted: 2017-08-01
• Last updated: 2019-01-22

Locations

1 site across 1 country: South Korea